By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panelists have mixed views on the attractiveness of MSFT, BDX, and CLX. While some see value in MSFT's growth potential and BDX's defensive income flows, others caution about execution risks, margin pressures, and potential multiple compression due to slow growth or recession. CLX faces demand destruction risks if consumer spending cracks.
Risk: Slow growth or recession leading to multiple compression
Opportunity: MSFT's Azure growth holding above 30% and BDX's pricing power in high-acuity clinical settings
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Microsoft shares look significantly undervalued.
Becton, Dickinson is a steady medical supply and device maker, with a growing dividend.
Clorox is working on getting more efficient and will pay investors well to wait.
It's tempting to want to fill your portfolio with lots of growth stocks. The best do offer chances at astronomical returns -- but they can also be overvalued and just as likely to pull back as to advance. So consider including some blue chip stocks in your mix.
A blue chip stock is one tied to a relatively stable, large, established company. blue chip stocks often pay dividends, which can be a big plus. While they may not grow as briskly as some growth stocks will, they can be less volatile. Actually, some blue chip stocks offer impressive growth, too!
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Here are three blue chip stocks to consider for your long-term portfolio. Each seems attractively priced as I write this, and will likely become even more so should the market pull back.
Microsoft (NASDAQ: MSFT) is a great example of a blue chip stock that's also a growth stock. It offers the best of both worlds -- relative stability and a rapid growth rate. The company, with a recent market value topping $3 trillion, has seen its shares deliver average annual gains of 21% over the past 15 years. In 2026, though, it's down roughly 12% at recent prices. That drop has made its shares even more attractively priced, with a forward-looking price-to-earnings (P/E) ratio of 22, well below the five-year average around 30. As my colleague Keithen Drury has noted, the stock hasn't been this cheap since 2019.
Part of the problem is that some investors are questioning the degree to which big tech companies like Microsoft are plowing money into artificial intelligence (AI) investments. That's a valid concern -- its capital expenditures over the trailing 12 months are more than double the comparable amount from just two years ago. But keep in mind that the stock is already significantly discounted and pays a growing dividend that recently yielded 0.9%. (Its annual dividend amount has grown from $2.09 in 2020 to $3.56 recently.)
Microsoft also remains a huge, diversified business, encompassing the dominant Office 365 suite of applications, the Azure cloud computing platform, the Xbox gaming platform, the Windows operating system, and even LinkedIn, among many other things.
Healthcare has been a rapidly growing sector for a long time, and it's likely to keep growing. One company poised to profit from that is Becton, Dickinson (NYSE: BDX), which also calls itself "BD."
The company is a leader in the development, manufacturing, and sale of medical supplies, devices, and diagnostic products. It earns much of its revenue from products such as catheters, syringes, blood collection tubes, specimen containers, biopsy needles, infusion systems, and medication dispensing systems -- items for which there will always be demand. (That demand results in recurring revenue, which is music to investors' ears.)
BD boasts that it cranks out more than 34 billion devices annually and spends heavily on research and development. Its 2025 annual report noted: "We built our strongest innovation pipeline ever in attractive end markets -- with more than 125 new products launched and an additional $1.3B added through over 20 accretive, high-growth tuck-in acquisitions."
It's also a dividend-paying stock, with a solid recent yield of 2.8%, and it has been upping its payout for more than 50 consecutive years. On top of that, BD has also been buying back shares, enough to hike its total shareholder yield (the dividend yield plus the effect of repurchases) to a recent 9%.
Meanwhile, BD's stock looks appealingly priced, with a recent forward-looking P/E ratio of 11.7, well below the five-year average under 17. Should the market pull back, the stock will likely hold up better than many growth stocks.
Then there's Clorox (NYSE: CLX), a very familiar name, and home to brands such as Brita, Burt's Bees, Clorox, Fresh Step, Glad, Hidden Valley, Kingsford, Liquid-Plumr, Pine-Sol, and recent addition Purell. It's not known for being a fast grower -- its stock has total annualized returns of just 5.4% over the past 15 years -- and over the past year, shares are down more than 25%.
That drop has made its shares appealingly priced, with a recent forward P/E ratio of 13, well below the five-year average of 24. It has also pushed up the stock's dividend yield to a compelling 5.1%. Add in share buybacks, and the total yield for shareholders is around 8%. (Clorox has hiked its payout for 48 years in a row, so you can bet that it's aiming to keep doing so.)
One headwind facing the company is the surging price of oil, which management expects will cost it more than $20 million in quarterly gross profit. Clorox has been working on cutting costs and becoming more efficient, and CEO Linda Rendle recently reported some positive news in its third-quarter conference call:
Most of our categories were positive, though, this quarter, which is good news. I think the important part to note here is that even though the consumer is under stress... they're still really resilient in our categories, and that's a good sign. We're seeing them continue to buy innovation. Private label shares did not increase this quarter. They're still shopping for brands.
Clorox looks like a promising stock to consider, if you're patient and seeking income.
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
Nvidia:if you invested $1,000 when we doubled down in 2009,you’d have $551,456!Apple:*if you invested $1,000 when we doubled down in 2008,you’d have $59,246!Netflix:if you invested $1,000 when we doubled down in 2004,you’d have $471,072!
Right now, we’re issuing “Double Down” alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon.
**Stock Advisor returns as of May 29, 2026. *
Selena Maranjian has positions in Microsoft. The Motley Fool has positions in and recommends Microsoft. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Microsoft's 22x forward P/E already embeds AI skepticism, so additional pullbacks may not produce the bargain the article assumes."
The article frames MSFT, BDX, and CLX as attractively valued after recent drops, citing forward P/Es well below five-year averages and solid dividend histories. Yet it underplays execution risks: Microsoft's doubled capex on AI may pressure margins if monetization lags, Becton's 34 billion devices face reimbursement pressure and acquisition integration risk, and Clorox's 5.1% yield comes amid $20 million quarterly oil-cost headwinds plus 5.4% long-term annualized returns. A broad market pullback could expose these names to further multiple compression rather than mean reversion.
Microsoft's diversified revenue and Azure growth could still justify a 22x multiple if AI spend delivers faster than expected, making today's price a genuine entry point the article correctly identifies.
"These stocks are cheaper than 2021 peaks, not cheap in absolute terms—and the article ignores that valuation compression often precedes earnings misses, not follows them."
The article conflates 'undervalued' with 'down from highs,' a critical distinction. MSFT at 22x forward P/E isn't cheap—it's merely cheaper than 30x. The real risk: if AI capex doesn't translate to revenue growth within 18-24 months, multiple compression accelerates. BD's 11.7x P/E looks attractive until you realize healthcare device makers face margin pressure from GPO consolidation and reimbursement headwinds. CLX's 5.1% yield is a value trap if oil costs persist and private label gains resume. The article ignores recession risk—all three are defensive, but CLX especially faces demand destruction if consumer spending cracks.
If AI monetization accelerates faster than consensus expects (Azure margin expansion, Copilot licensing), MSFT could re-rate to 28-30x despite higher rates. BD's recurring revenue and 50-year dividend streak genuinely insulate it better than the article suggests.
"While MSFT offers a rare valuation reset for a high-quality compounder, BDX and CLX are likely value traps facing structural headwinds that dividend yields alone cannot offset."
The article presents a classic 'defensive value' rotation, but it glosses over the fundamental divergence between these picks. Microsoft (MSFT) at a 22x forward P/E is a legitimate growth-at-a-reasonable-price (GARP) play, provided Azure growth holds above 30%. However, Becton, Dickinson (BDX) and Clorox (CLX) are essentially yield traps masquerading as value. BDX faces significant margin compression from hospital labor costs and supply chain volatility, while Clorox is fighting a losing battle against private-label penetration in a price-sensitive consumer environment. Investors buying these for 'safety' may find the dividend yield is merely compensation for stagnant top-line growth and long-term multiple contraction.
If the macro environment shifts toward a recession, the defensive nature of BDX and CLX will outperform the high-beta volatility of tech, making their lower valuations a feature, not a bug.
"MSFT remains a core long-term holding, but near-term upside hinges on whether AI investments translate into material earnings acceleration rather than just headlines."
MSFT's AI capex is a double-edged sword: big investments now could weigh on near-term margins and earnings growth, even as the stock trades at a forward P/E of about 22, not inexpensive for a 'best-of-breed' with mixed growth signals. BDX appears cheap at ~11.7x forward earnings and 2.8% dividend, but its growth is tied to healthcare cycles and reimbursement patterns; CLX offers ~13x forward earnings and a 5.1% dividend, yet commodity-cost sensitivity (oil) and consumer-spending headwinds loom. The piece glosses over macro risks, rate sensitivity, and the possibility that AI-driven demand may disappoint in the short run, limiting multiple expansion.
AI spend could fail to translate into meaningful near-term revenue, leaving margins and earnings growth under pressure. A macro pullback or rate shock could compress multiples further, even for these so-called blue chips.
"BDX's payout durability offers hidden downside protection in a downturn that the panel has not connected to its valuation."
Claude flags recession demand destruction for CLX but misses how BDX's recurring device revenue and 50-year payout streak could draw defensive income flows even if hospital capex slows. That dynamic might limit multiple compression below 11.7x more effectively than MSFT's Azure growth can protect its 22x multiple if AI monetization slips by even one quarter.
"Dividend safety and valuation compression are orthogonal—BDX's payout streak doesn't anchor its P/E multiple if growth disappoints."
Grok's point on BDX's defensive income flows is sound, but it conflates stability with valuation. A 50-year dividend streak doesn't prevent multiple compression if growth stalls—it just means the yield rises as the stock falls. The real question: does 11.7x reflect fair value for low-single-digit growth, or is it a trap? Nobody's addressed whether hospital capex cycles are actually weakening now versus priced-in.
"Regulatory supply-side constraints in medical device sterilization provide a structural margin moat for BDX that the market is currently mispricing."
Claude, you’re missing the regulatory tailwind for BDX. While you focus on GPO consolidation, you ignore the impact of the FDA’s recent crackdown on medical device sterilization plants. This creates a supply-side barrier to entry that protects BDX’s margins far more than a dividend streak ever could. The 'low growth' narrative is stale; BDX is effectively pricing in a worst-case scenario that ignores their moat in high-acuity clinical settings where pricing power remains surprisingly robust.
"Regulatory risk around FDA sterilization could erode BDX’s moat, compressing the multiple if growth slows."
Gemini’s strike on BDX’s moat hinges on FDA sterilization crackdowns delivering durable pricing power. But higher compliance costs, potential plant delays, and capex demands could erode margins even with a supply-side barrier. A regulatory win is not a long-run dividend guarantee if hospital volumes stall or if reimbursements bite. The result: BDX’s 11.7x forward multiple may still compress if growth slows and the perceived safety yield proves transitory.
The panelists have mixed views on the attractiveness of MSFT, BDX, and CLX. While some see value in MSFT's growth potential and BDX's defensive income flows, others caution about execution risks, margin pressures, and potential multiple compression due to slow growth or recession. CLX faces demand destruction risks if consumer spending cracks.
MSFT's Azure growth holding above 30% and BDX's pricing power in high-acuity clinical settings
Slow growth or recession leading to multiple compression